Key result
Platelet releasate contains ~300 proteins that may drive atherosclerosis progression and offer new therapeutic targets.
The platelet releasate contains numerous pro-inflammatory factors that drive atherosclerosis, presenting a potential target for therapeutic intervention.
Answers are grounded in this paper and cite their sources.
May support targeting platelet releasate proteins in atherosclerosis; hypothesis-generating and requires prospective validation before clinical consideration.
The platelet releasate comprises of a multitude of inflammatory and vasoactive substances, which can attract atherogenic leukocytes from the circulation, activate endothelial cells and stimulate vessel growth and repair by triggering vascular cell proliferation, migration, and inflammation. Thus, platelets are believed central in the development and progression of atherosclerotic lesions and recent progress in uncovering more than 300 proteins in the thrombin-activated platelet releasate may advance our ability to understand the events involved and responses triggered in the progression of atherosclerosis. Furthermore, neutralisation of these platelet-derived pro-inflammatory factors may become an interesting means for therapeutic or preventative intervention in atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Coppinger et al. (2007) conducted a review in Atherosclerosis. Platelet releasate was evaluated. The platelet releasate contains over 300 proteins that may drive the development and progression of atherosclerotic lesions, presenting a potential target for therapeutic intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: